Biology subjects

Nimeus, E.

Publications and source records attributed to Nimeus, E..

3 recordsLinked to original sources

bioRxiv2024

Inferring the composition of the blood plasma proteome by a human proteome distribution atlas

The plasma proteome is maintained by the influx and efflux of proteins from surrounding organs and cells. To quantify the extent different organs and cells contribute to the plasma proteome composition, we developed a mass spectrometry-based proteomics strategy to infer the origin of proteins detected in human plasma in health and disease. First, we constructed an extensive human proteome atlas from 18 vascularized organs and the most abundant cell types in blood. Second, the atlas was interfaced with previous RNA/protein atlases to objectively define proteome wide protein-organ associations to enable both the inference of origin and the reproducible quantification of organ-specific proteins in plasma. We demonstrate that the resource can determine disease-specific quantitative changes of organ-enriched protein panels in three separate patient cohorts with infection, pancreatitis, and myocardial injury. The strategy can be extended to other diseases to advance our understanding of the processes contributing to plasma proteome dynamics.

systems biology↗

bioRxiv2022

Evolution of ipsilateral breast cancer decoded by proteogenomics

Ipsilateral breast tumor recurrence (IBTR) is a clinically important event, where an isolated in-breast recurrence is a potentially curable event but also associated with an increased risk of distant metastases and breast cancer death. It currently remains unclear if IBTRs are associated with molecular changes that can be explored as a resource for precision medicine strategies targeting locally recurring breast cancer. Here, we employed a recently developed proteogenomics workflow to analyze a cohort of 27 primary breast cancers and their matched IBTRs by whole genome sequencing, RNA sequencing, and mass spectrometry-based proteomics to define proteogenomic features of tumor evolution. Analysis of mutational signatures, copy number changes, and cancer specific mutations revealed a relationship with estrogen and progesterone receptor statuses and increased levels of genetic change. This in turn altered the re-programming of the transcriptome and proteome towards a recurring molecular disease phenotype with high replicating capacity and a higher degree of genomic instability possibly enhanced by high expression of APOBEC3B. In conclusion, this study defines how primary breast tumors differentially evolve into different ipsilateral recurrent malignancies depending on their key biomarker status, suggesting that further enhancing the genomic instability in some tumors could serve as an alternative treatment option.

cancer biology↗

bioRxiv2020

A Proteogenomic workflow reveals distinct molecular phenotypes related to breast cancer appearance

Proteogenomics approaches have enabled the generation of extensive information levels when compared to single omics technology studies, although burdened by massive experimental efforts. Here, we developed four improvements of a data independent acquisition mass spectrometry proteogenomics workflow to reveal distinct molecular phenotypes related to breast cancer appearance. We confirm mutational processes detectable at the protein level and highlight quantitation and pathway complementarity between RNA and protein data. Our analyses also validated previously established enrichments of estrogen receptor-dependent molecular features relating to transcription factor expression, and provided evidence for molecular differences related to the presence of mammographic appearances in spiculated tumors. In addition, several transcript-protein pairs displayed radically different abundance correlations depending on the overall clinical and pathological properties of the tumor. These results demonstrate that there are differentially regulated protein networks in clinically relevant sample groups, and that these protein networks influence both cancer biology as well as the abundance of potential biomarkers and drug targets.

systems biology↗